Journal article
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs
Abstract
AIMS OF THE STUDY: Hydroxychloroquine and lopinavir/ritonavir have been used as experimental therapies to treat COVID-19 during the first wave of the pandemic. Randomised controlled trials have recently shown that there are no meaningful benefits of these two therapies in hospitalised patients. Uncertainty remains regarding the potential harmful impact of these therapies as very early treatments and their burden to the health care system. The …
Authors
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny J-L; Samer C
Journal
Swiss Medical Weekly, Vol. 150, No. 5153,
Publisher
SMW Supporting Association
DOI
10.4414/smw.2020.20446
ISSN
1424-7860
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdolescentAdultAge FactorsAgedAged, 80 and overAntiviral AgentsCOVID-19ChildChild, PreschoolComorbidityDrug CombinationsDrug Therapy, CombinationHealth ExpendituresHospital MortalityHumansHydroxychloroquineInfantLength of StayLopinavirMiddle AgedPandemicsRetrospective StudiesRitonavirSARS-CoV-2Severity of Illness IndexSex FactorsSocioeconomic FactorsTherapies, InvestigationalYoung AdultCOVID-19 Drug Treatment